Navigation Links
Caliper Enters Agreement to Divest Non-Core Pharmaceutical Development & Quality Analysis Product Line
Date:10/29/2008

- Sale Reinforces Strategic Focus and Enhances Cash Position -

HOPKINTON, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced that it has reached an agreement to sell its Pharmaceutical Development & Quality Analysis (PDQ) product line to SOTAX Corporation in a transaction valued at approximately $15.8 million. The PDQ product line consists of products used for drug content uniformity and dissolution rate testing and related services. The sale is expected to close in November 2008.

"Divesting the PDQ product line is an important milestone in our strategy to focus on core technologies in imaging, microfluidics and sample preparation and to strengthen our balance sheet by rationalizing non-strategic product segments," said Kevin Hrusovsky, President and CEO of Caliper. "A sharper strategic focus can facilitate an increased top line growth rate and potential for achieving further operating efficiencies, accelerating our timeline to profitability."

Under the terms of the agreement, SOTAX, a leader in technologies used for tablet testing, will make a cash payment of approximately $13.8 million and assume liabilities for an estimated $2 million. Furthermore, Caliper and SOTAX have expressed their intent to enter into a long-term lease agreement under which Caliper will sublease approximately 10,000 square feet of manufacturing and office space to SOTAX on a market-rate basis, thereby reducing Caliper's ongoing facility costs. Certain Caliper employees currently involved with the PDQ business will be offered positions with SOTAX.

"This acquisition represents an opportunity for SOTAX to expand its worldwide presence, especially in the United States and the United Kingdom, and is an important step in achieving our strategic growth objectives," said Rolf Benz, President and CEO of SOTAX Holding A.G. the privately-owned parent company of SOTAX Corporation. "Caliper built excellent customer relationships in this market segment and is working closely with us to ensure that the PDQ customers continue to receive the same exceptional level of customer support and service throughout the transition and beyond."

Caliper's PDQ product line is comprised of TPW3(TM) -- Tablet Processing Workstation, APW3(TM) -- Active Ingredient Processing Workstation, MultiDose(R) G3 - Dissolution Workstation, and other related products.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.

The statement in this press release regarding future events, including Caliper's belief that the divestiture of the PDQ product line can facilitate an increased top line growth rate and potential for achieving further operating efficiencies, thus accelerating its timeline to profitability is a "forward-looking statement" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. This statement is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements as a result of a number of factors, including the possibility that for unforeseen reasons the divestiture of the PDQ product line might not be completed as contemplated. Further information on risks faced by Caliper are detailed under the caption "Risks Related To Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2007. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release.

Caliper, TPW3, APW3 and MultiDose are trademarks of Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences Third Quarter 2008 Financial Results Conference Call Notice
2. Caliper Life Sciences and DiscoveRx Announce Availability of PathHunter eXpress Reagents for GPCR Assays
3. Caliper Life Sciences to Present at UBS Global Life Sciences Conference
4. Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation
5. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
6. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
7. Caliper Life Sciences Reports Second Quarter 2008 Results
8. Caliper Life Sciences Second Quarter 2008 Financial Results Conference Call Notice
9. Caliper Life Sciences Added to Russell 3000(R) Index
10. Caliper Life Sciences to Present at Deutsche Banks 33rd Annual Health Care Conference
11. Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ALBANY, New York , March 23, 2017 ... animal blood plasma products and derivatives market is fragmented due to the ... large players, such as Proliant, Thermo Fisher , and Sigma-Aldrich, ... clear leader, these three companies, collectively, held more than 76% of ... ...
(Date:3/22/2017)... ... 2017 , ... Researchers face a fundamental challenge as they ... tissues, bones, even whole organs to implant in people to treat disease or ... the developing tissue. , Current bioengineering techniques, including 3-D printing, can’t fabricate ...
(Date:3/22/2017)... , March 22, 2017   iSpecimen ®, ... that Doctors Pathology Service (DPS), a full-service ... the United States , has joined ... Health Information Network (DHIN) to make human biospecimens ... The novel program, announced in 2015 as a ...
(Date:3/22/2017)... Pa. , March 22, 2017 /PRNewswire/ ... global independent provider of product and service ... today that it has acquired EPL Archives, ... supports customers across the entire regulated product ... archive sample, document storage and ancillary services. ...
Breaking Biology Technology:
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , ... software globally, announces significant enhancements to new and core ... 2016. New products include mobile and desktop Acuant FRM ... TM - a real time manual review of ... idScan® technology provides the fastest and most accurate capture ...
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
Breaking Biology News(10 mins):